Pharmaceutical Business review is using cookies

ContinueLearn More
Close
November 14, 2018

AbbVie’s Mavyret shows high virologic cure rates in HCV study

AbbVie’s Mavyret (glecaprevir/pibrentasvir) has showed high virologic cure rates in treatment-naïve patients with compensated cirrhosis in the phase 3b Expedition-8 study.

Image: AbbVie US headquarters. Photo: courtesy of AbbVie Inc.